Patent intelligence · US
US 8153116
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
Patent details — US 8153116
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 10, 2012
- Expiration
- Apr 5, 2032
- Applicant
- UNIVERSITY OF CONNECTICUT
- Claims
- 15
- CPC classes
- A61K, A61K2039/5254, A61K39/015
Quick answer
US 8153116 (Use of conditional plasmodium strains lacking an essential gene in malaria vaccination) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Apr 10, 2012. Expires Apr 5, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- UNIVERSITY OF CONNECTICUT
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/5254, A61K39/015
More from UNIVERSITY OF CONNECTICUT
Related pharmaceutical patents in our USPTO index.
-
US 12311017
Identification of immunologically protective neo-epitopes for the treatment of cancers
granted -
US 12251378
Long-acting local anesthetic formulation
granted -
US 12202822
Addition salt of S1P1 receptor agonist and crystal form thereof, and pharmaceutical composition
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12029787
Method for generating recombinant poxviruses
granted -
US 12018255
Compositions and methods for treating disorders of genomic imprinting
granted -
US 11952419
Reagents and methods for treating cancer and autoimmune disease
granted
Frequently asked questions
What is US patent 8153116?
US 8153116 (Use of conditional plasmodium strains lacking an essential gene in malaria vaccination) is held by UNIVERSITY OF CONNECTICUT. Status: granted. Granted Apr 10, 2012. Expires Apr 5, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8153116?
UNIVERSITY OF CONNECTICUT is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 179 pharmaceutical patents for this assignee.
When does US 8153116 expire?
Our index shows an expiration date of Apr 5, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.